Vista Pharmaceuticals Share Price Today | Stock Price & Vista Pharmaceuticals Share Screener
As of October 5, 2026, the live Vista Pharmaceuticals share price (BSE: VISTAPH) is ₹5.83, down 6.12% from the previous close, with shares trading between ₹5.74 and ₹6.45 in today's trading session, and a 52-week range of ₹5.36–₹10.06. Check VISTAPH 52-week high low for the annual price range and momentum. Use the Vista Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Vista Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹4 and net income of ₹-12, with EBITDA of ₹-14, an operating margin of -90.0% and a profit margin of -300.0%.
Vista Pharmaceuticals Share Price Chart
Track the current stock price of Vista Pharmaceuticals with an interactive chart. Analyse VISTAPH share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Vista Pharmaceuticals stock quote in one place.
The quote of ₹5.83 sits between the 52-week low of ₹5.36 and the 52-week high of ₹10.06, and the latest session moved -6.12% from the previous close.
Vista Pharmaceuticals Company Profile - Fundamental Screener
Screen Vista Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for VISTAPH shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE427C01021.
Company Details
Classification
Identifiers and Leadership
Vista Pharmaceuticals Balance Sheet Screener
Screen VISTAPH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹55, down from ₹60 in 2025.
Latest statistics put total assets at ₹55 and shareholder funds at ₹36, with a leverage ratio of 0.18.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 55 | 60 | 58 | 56 | 56 | 51 | 51 | 53 | 53 | 42 |
| Current Assets | 15 | 25 | 23 | 24 | 24 | 15 | 21 | 23 | 28 | 26 |
| Fixed Assets | 29 | 19 | 19 | 20 | 19 | 20 | 21 | 21 | 18 | 14 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 2 | 3 | 3 | 5 | 8 | 9 | 6 | 6 | 6 | 6 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 36 | 45 | 41 | 37 | 36 | 33 | 30 | 36 | 32 | 17 |
| Share Capital | 12 | 12 | 9 | 8 | 7 | 7 | 6 | 6 | 6 | 5 |
| Reserves & Surplus | 24 | 33 | 26 | 23 | 28 | 26 | 24 | 30 | 26 | 11 |
Vista Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Vista Pharmaceuticals income statement and profit fundamentals. Analyze VISTAPH quarterly results. Vista Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹4 and net profit was ₹-12, equal to earnings per unit of ₹-1.90, at an operating margin of -90%.
In that period expenses were ₹18, interest cost ₹1 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹5 and net profit of ₹-16.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 4 | 5 | 11 | 11 | 1 | 1 | 2 | 27 | 34 | 29 | 24 | 15 | 14 |
| Expenses | 18 | 20 | 14 | 14 | 5 | 2 | 3 | 28 | 30 | 24 | 21 | 13 | 11 |
Operating Costs and Margins | |||||||||||||
| EBITDA | -14 | -15 | -4 | -3 | -4 | -1 | -2 | -1 | 4 | 6 | 3 | 3 | 3 |
| Operating Profit % | -90.00% | -271.00% | -40.00% | -32.00% | -443.00% | -321.00% | -137.00% | -21.00% | 4.00% | 18.00% | 13.00% | 17.00% | 20.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 0 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | -16 | -16 | -5 | -5 | -6 | -3 | -4 | -4 | 1 | 3 | 1 | 1 | 1 |
| Tax | 0 | 0 | -1 | -1 | 0 | -2 | -2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Net Profit | -12 | -16 | -5 | -5 | -6 | -1 | -2 | -4 | 1 | 2 | 1 | 1 | 1 |
| EPS | -1.90 | -1.96 | -0.79 | -1.03 | -1.54 | -0.24 | -0.54 | -1.22 | 0.31 | 0.76 | 0.46 | 0.31 | 0.54 |
Vista Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen VISTAPH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities used ₹7, and net cash flow was an inflow of ₹1.
Over the same period, investing activities provided ₹0 and financing activities provided ₹8.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | -7 | -5 | -2 | -1 | -7 | 1 | 3 | -5 | 3 | -3 |
| Investing Activities | 0 | -1 | -1 | 0 | 0 | -2 | -6 | -11 | -4 | 0 |
Financing and Net Cash | ||||||||||
| Financing Activities | 8 | 6 | 3 | 1 | 7 | 0 | 1 | 11 | 6 | 3 |
| Net Cash Flow | 1 | 0 | 0 | 0 | 0 | -1 | -1 | -4 | 5 | 0 |
Vista Pharmaceuticals Shareholding Pattern Screener
See Vista Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Vista Pharmaceuticals promoter holding and ownership changes for VISTAPH on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Jun, promoters held 21.19%, foreign institutions 0.00%, domestic institutions 0.02% and the public 33.63%, spread across 14,154 shareholders.
The shareholder count was 14,154 in 2026-Jun, compared with 14,154 in 2026-Mar.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 33.63% | 33.63% | 33.63% | 33.64% | 33.62% | 33.62% | 34.00% | 33.86% |
| Other Holding | 45.17% | 45.17% | 45.16% | 45.16% | 45.17% | 45.17% | 44.79% | 44.93% |
| Shareholder Count | 14,154 | 14,154 | 14,080 | 14,012 | 14,061 | 14,158 | 14,086 | 13,913 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Vista Pharmaceuticals. Vista Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.
Vista Pharmaceuticals Stock Index Membership - Nifty & Sensex
See which indices include Vista Pharmaceuticals stock. Check VISTAPH index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Vista Pharmaceuticals Market Events Screener - Corporate Actions
Get Vista Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Vista Pharmaceuticals stock events that may affect VISTAPH share price, along with derivatives, futures and options activity and sector gainers.
12 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated August 14, 2026, with a record date of August 14, 2026.
It is followed by Quarterly Result Announcement dated May 29, 2026 and Quarterly Result Announcement dated February 13, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | 1.17% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 10.19% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | -6.06% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -0.83% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -12.39% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | 4.83% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -0.27% |
| 2025-03-20 | 2025-03-20 | Extraordinary General Meeting | NA | -0.65% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | 11.02% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | -1.49% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | 4.18% |
| 2024-03-06 | 2024-03-06 | Extraordinary General Meeting | NA | -9.45% |
Vista Pharmaceuticals Competitors Screener - Peer Stocks Comparison
Screen VISTAPH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 36.04 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.24 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.71 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 25.27 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.50 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.20 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.04 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 32.41 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.84 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.82 | 29,039 | 26.75% | 5,356 | 31.59 |
Vista Pharmaceuticals Company Announcements - News & Reports Screener
Screen VISTAPH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated September 12, 2026.
The next most recent announcements are dated August 14, 2026 and August 14, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-09-12 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | - |
| 2026-08-14 | Board Meeting Outcome for Results For The Quarter Ended 30.06.2026 | - |
| 2026-08-14 | Results For The Quarter Ended 30.06.2026 | - |
| 2026-08-13 | Board Meeting Intimation for Approval Of Un Audited Financials Results For The Quarter Ended 30.06.2026 | - |
| 2026-07-15 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-25 | Closure of Trading Window | - |
| 2026-05-29 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-29 | Outcome Of Board Meeting Under Regulations 30 Read With 33 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-05-19 | Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ended 31.03.2026 | - |
| 2026-04-29 | Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 | - |
| 2026-04-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-27 | Closure of Trading Window | - |
| 2026-02-13 | Board Meeting Outcome for Un Audited Financial Results For The Quarter Ended 31.12.2025 | - |
| 2026-02-13 | Results For The Quarter Ended 31.12.2025 | - |
| 2026-02-05 | Update on board meeting | - |
| 2026-02-05 | Board Meeting Intimation for 1. Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2025. 2. Limited Review Report Quarter And Nine Months 31.12.2025. 3. Any Other Business With The Permission Of The Chair. | - |
| 2026-02-03 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Joint Venture Partnership Between Pleiades Therapeutics And Vista Pharmaceuticals Ltd | - |
| 2026-01-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-30 | Closure of Trading Window | - |
| 2025-11-13 | Board Meeting Outcome for Un Audited Financial Results For The Quarter And Half Year Ended 30.09.2025 | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹5.83, within a 52-week range of ₹5.36 to ₹10.06. The P/E ratio is -3.30 and the P/B ratio is 1.07, with earnings per unit of ₹-1.96. Market capitalisation stands at ₹38.06 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.